maintain an international normalized ratio (INR) Ͻ 2, was effective, as compared with placebo, in reducing obstruction of bypass grafts. The results showed that aggressive lowering of LDL cholesterol levels reduced the progression of atherosclerosis in grafts. Low-dose anticoagulation therapy did not reduce the progression of atherosclerosis. 1 In the extended follow-up phase, reduced rates of clinical events were observed in the groups assigned to aggressive lowering of LDL cholesterol levels and in the groups assigned to low-dose anticoagulants. 2 The clinical and angiographic benefits of lipid-lowering therapies are now well recognized. [3] [4] [5] [6] [7] [8] Furthermore, the efficacy and safety of the statin class of lipidlowering drugs has resulted in widespread clinical use of these agents.
The Lipid Research Clinic Coronary Primary Prevention Trial (LRC-CPPT) 9 investigators reported an increased risk for accidental death and suicide in patients randomly assigned to cholestyramine, compared to patients assigned to placebo. The Helsinki Heart Study, 10 a primary prevention trial of lipidlowering therapy using gemfibrozil, also reported that patients randomized to gemfibrozil experienced more deaths due to violence and accidents than patients assigned to placebo. These early observations from the LRC-CPPT and the Helsinki Heart Study were important in the controversy about whether there was a causal relationship between lipid-lowering therapy and noncardiovascular mortality. Muldoon et al 11 published results of a metaanalysis reporting that lipid-lowering interventions, including diet, clofibrate, colestipol, cholestyramine, and gemfibrozil, tended to lower coronary deaths, but not overall mortality, with an apparent excess of deaths not related to disease (accidents, suicide, or violence). Subsequent analyses that included data from the statin class of lipid-lowering therapy suggested that the excess of noncardiovascular mortality observed in some clinical trials may be related to particular classes of therapy, specifically fibrates and hormones, rather than to lipid lowering. 12 Nevertheless, some investigators speculated that the association noted by Muldoon et al 11, 13 could be explained by negative effects of lipid lowering on neurochemistry or behavior, for example with depression or violent behavior as mediating conditions. 14, 15 There have been some observational and experimental studies 16 -18 that showed correlations between relatively low lipid levels and depression, risk of suicide, and other disorders or adverse outcomes. Results of other studies 19, 20 suggest that lipid-lowering interventions do not influence health-related quality of life (HRQL), or even have positive effects on conditions such as depression. These studies have differed widely with regard to baseline characteristics of patients, interventions under evaluation (behavioral or pharmacologic, class of pharmacologic agent), length of follow-up (weeks to years), and outcome measures (sleep disorders to comprehensive qualityof-life questionnaires).
There have been limited evaluations of the effects of warfarin therapy on HRQL. The results of the Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) suggested that warfarin therapy that results in an INR range of 1.5 to 2.5 was not generally associated with changes in measures of functional status, well being, and perceived health. However, patients who experienced a bleeding episode showed decreases in perceived health. 21, 22 In the POST CABG Trial, we examined the effects of both lipid-lowering and low-dose anticoagulation therapy on HRQL.
Materials and Methods
Institutional review board approvals were obtained at each participating center, and informed consent was obtained from each patient enrolled. HRQL measures involving psychosocial and physical well being were obtained through a self-administered questionnaire at baseline (randomization visit), and at the year-2 and year-4 follow-up visits. Patients completed the questionnaire during a clinic visit or at home. Domains included emotional status based on assessment of anxiety, scored on a scale of 20 to 80, with higher scores indicating increased anxiety (Spielberger State Anxiety Inventory 23 ), and depression, scored on a scale of 0 to 60, with higher scores indicating more depressive symptoms and a screening score Ն 16 considered to warrant further evaluation (Center for Epidemiologic Studies Screening Test for Depression [CES-D]). 24 Basic physical functioning and social functioning were evaluated with the functional status questionnaire, scored on a scale of 0 to 100%, with 100% indicating that all functions can be performed with no difficulty whatsoever. 25 Additional factors assessed included the patients' perceived health status, 26 pain symptom levels (McGill pain questionnaire), 27 a variety of physical symptoms based on patient recall, and global life satisfaction at present and anticipated 5 years hence. 28 Their measurement has been described in detail. 28, 29 A summary of the HRQL domains and measures used is provided in Table 1 .
The details of the design of the POST CABG Trial have been reported previously. 1 Eligibility criteria included men and women aged 21 to 74 years who underwent CABG procedures 1 to 11 years earlier. In a 2 ϫ 2 factorial design, patients were randomly assigned to aggressive LDL cholesterol lowering using lovastatin (and cholestyramine, as necessary) aimed to achieve a LDL cholesterol goal of 60 to 85 mg/dL (1.6 to 2.2 mmol/L), compared to moderate LDL cholesterol lowering (same medications in lower doses) to achieve a LDL cholesterol goal of 130 to 140 mg/dL (3.4 to 3.6 mmol/L). Patients were also randomly assigned to receive warfarin or placebo; the warfarin dose (1 to 4 mg) was titrated to achieve a mean INR Ͻ 2.
Statistical Analysis
Comparisons of proportions of patient groups having given attributes were made with 2 tests, with one degree of freedom for unadjusted two-group comparisons. 30 For continuous data, mean values (Ϯ SD) are presented, and comparisons were made with two-sample t tests. 31 Tests for homogeneity of the effects among treatment groups were performed for proportions using the Mantel-Haenzel method and for continuous data with interaction terms in analysis of variance models. 30, 31 Because no important interactions were detected, the results were pooled for single comparisons of treatment effects, and p values used are two sided without correction for multiple comparisons. Because many comparisons are made in these analyses, some p values Ͻ 0.05 would be expected due to chance, and can only be interpreted as suggesting associations; p Ͻ 0.01 provides some evidence, and p Ͻ 0.001 provides strong evidence of associations. The number of patients whose data are included in this analysis was determined by the enrollment and timing of the POST CABG Trial. With the number of patients in each treatment group, comparisons of an ␣ level of 0.01 were made with 80% power for differences of 0.35 SDs and 90% power for differences of 0.39 SDs. The analyses were performed using the SAS statistical package (SAS Institute; Cary, NC).
Results

Patient Characteristics
The characteristics of the POST CABG Trial patients have been described elsewhere. 1 A total of 852 of the 1,351 patients enrolled in the POST CABG Trial completed the HRQL questionnaire at the randomization visit, year 2, and year 4, and are referred to as the HRQL cohort and are included in the analyses reported in this article. The majority of patients (n ϭ 316) who were excluded did not complete the questionnaire at baseline, primarily because the questionnaire was not put into use until some months after the initiation of the POST CABG Trial. Forty-eight patients died prior to the year-4 assessment and are not included in the analysis (13 patients in the aggressive treatment plus warfarin group, 10 patients in the aggressive treatment plus placebo group, 9 patients in the moderate treatment plus warfarin group, and 16 patients in the moderate treatment plus placebo group).
The baseline characteristics of 852 patients included in the analysis were compared to those of the 499 patients who were not included (Table 2) . A slightly higher percentage of patients who were 26 Based on patients ranking of their perceived health as excellent, very good, good, fair, or poor.
Symptoms of pain
McGill pain questionnaire short form 27 Scale of 0-45, based on 15 items in the affective and sensory dimension. Each item is scored 0 to 3, with 0 corresponding to the absence of the symptom and 3 corresponding to severe symptoms. Physical symptoms Study-specific questions Life satisfaction
Ladder of life 28 Based on patient's assessments of their overall life satisfaction, with a score of 0 corresponding to their perception of the worst possible life and a score of 10 corresponding to their perception of the best possible life. included in the HRQL cohort had undergone CABG within the past 5 years (57% vs 52%, p ϭ 0.07). A lower percentage of patients in the HRQL cohort had a family history of coronary heart disease (68% vs 74%, p ϭ 0.02) or a family history of myocardial infarction (47% vs 53%, p ϭ 0.02). A higher percentage of patients in the HRQL cohort were receiving aspirin at baseline (80% vs 68%, p ϭ 0.001). Patients in the HRQL cohort had a slightly higher mean age (61.9 years vs 60.9 years, p ϭ 0.01).
HRQL
The HRQL results are summarized in Tables 3-7 . Overall, there were no indications of systematic differences among treatment groups for any of the HRQL parameters at baseline, year 2, or year 4.
Specifically, the mean scores on the Spielberger State Anxiety Inventory were 30 to 32 (Table 3) . The average scores for the CES-D scale were 5.8 to 7.0. There is a small difference between the warfarin and placebo groups at year 2 (7.0 vs 5.8, p ϭ 0.02).
Subscales of the functional status questionnaire for self report of basic physical functioning and social functioning averaged Ͼ 95%, with the large majority of patients responding that they were able to perform all the basic physical and social activities (Table  4 ). There was a small difference at baseline between the aggressive treatment group and the moderate treatment group (97.8% vs 98.9%, p ϭ 0.02) that was not present at the later observation periods.
The patients' reports of symptoms are summarized in Table 5 . Tiredness was experienced at least once per week for approximately half the patients. Fewer than one fourth of patients experienced chest pain or shortness of breath at least once per week. There were no indications of changes in these symptoms during the 4-year follow-up period. Approximately one third of patients reported trouble sleeping at least once a week. Fewer than 20% of patients reported trouble concentrating at least once a week. Less than 10% had problems eating at least once a week. Edema at least once per week was reported for slightly more patients in the aggressive LDL cholesterol-lowering treatment group at year 4 (19% vs 13%, p ϭ 0.02). Approximately one third of patients experienced forgetfulness at least once per week, and approximately 40% experienced muscle aches and pains at least once a week. The McGill pain scale scores averaged 3.5 to 4.7, with no consistent differences among treatment groups or over time (Table 6 ).
Patients were asked to rank their overall "global life satisfaction" on the "ladder of life." The average score "at present" was 7.9 to 8.2, with similar atpresent scores reported at baseline, year 2, and year 4 ( Table 6 ). The patients anticipated their global life satisfaction 5 years in the future to be somewhat higher, with scores averaging 7.8 to 8.5, with small differences between the warfarin and placebo groups at year 2 (7.9 vs 8.4, p ϭ 0.002) and year 4 (7.8 vs 8.1, p ϭ 0.02).
The majority of patients ranked their health as excellent or very good; Ͻ 25% ranked their health as fair or poor (Table 7) . These responses were consistent across treatment groups and at all three time points.
Discussion
This study shows that long-term treatment to lower LDL cholesterol levels, effective in reducing progression of atherosclerosis, was not associated with any detrimental or beneficial effects on HRQL parameters, including symptoms of depression and anxiety over a 4-year period. These observations are especially noteworthy because of the approach to lipid lowering that was used in the aggressive LDL cholesterol-lowering treatment group. In the aggressive LDL cholesterol-lowering treatment group, the mean LDL cholesterol level at 1 year was 93 mg/dL, and 66% of the participants had LDL cholesterol levels Ͻ 100 mg/dL. In both the 4-year and longer follow-up assessments, these reductions in LDL cholesterol levels were associated with clinically and statistically significant improvements in the angiographic end points, and favorable trends in clinical events, including a reduced number of revascularization procedures (coronary artery bypass graft [CABG] or percutaneous transluminal coronory angioplasty). 1,2 The absence of any adverse effect on HRQL parameters, including symptoms of depression (as measured on the CES-D, which standardizes the inquiry for symptoms to screen for individuals for whom a proportion will be diagnosed with clinical depression, a proposed precursor of suicide in other writings on noncardiovascular mortality and lipidlowering therapy), is reassuring as increasing numbers of patients are being treated with medications to lower LDL cholesterol levels to ranges that are comparable to those in the aggressive LDL cholesterol-lowering treatment group of the POST CABG Trial. Treatment with warfarin was not associated with an impact on HRQL parameters, nor was it associated with changes in angiographic measures or clinical events in the POST CABG Trial. The BAATAF investigators 21, 22 observed that patients who experienced a bleeding event during treatment with warfarin experienced a decrease in their perception of their health status. Patients treated with warfarin in BAATAF had an INR of 1.5 to 2.5 and a slight increase in risk of bleeding events. In contrast, patients randomly assigned to warfarin treatment in the POST CABG Trial had a lower average INR of 1.4, and no excess risk of bleeding that required hospitalization and/or transfusion was detected. Accordingly, the current observations may be attributable to the low level of anticoagulation achieved in the POST CABG Trial.
It is noteworthy that the study patient population showed generally very positive scores on all components of the HRQL assessment at study entry and on 2-year and 4-year follow-up. The activities of daily living scales showed high levels of basic physical and social functioning. A minority of patients reported clinical symptoms such as chest pain or shortness of breath once a week or more often. It seems likely that the overall positive HRQL status reflects the selection of patients with the physical, psychological, and social resources needed to participate in this long-term clinical trial. These patients had undergone CABG surgery a minimum of 1 year and an average of 4.3 years prior to study entry. Accordingly, the majority were well beyond the perioperative period, when patients generally have lower HRQL scores. 29 These results are consistent with the findings of the Randomized Intervention Treatment of Angina Trial 32 that relief of angina by percutaneous transluminal coronary angioplasty or CABG is associated with positive perceived health status. Also, the absence of any finding of improved HRQL scores in association with aggressive lipid-lowering therapy provides a cautionary note. Hypercholesterolemia is a silent killer like high BP. Not until there are severe abnormalities in the coronary artery anatomy do patients have symptoms or reduced HRQL scores. Patients must be encouraged to comply with aggressive lipid-lowering treatments with the expectation that the therapy will prevent unnecessary losses in quality of life instead of the expectation of rapid and noticeably improved quality of life.
The suspicion that reduction in cholesterol might be associated with increased risk of violent death (eg, accidental death, suicide) was initially raised in the context of two randomized, double-blind, placebo controlled clinical trials: the LRC-CPPT 9 and the Helsinki Heart Study. 10 In the LRC-CPPT, cholesterol lowering with cholestyramine was associated with a reduction in coronary heart disease events. Among the patients who died of noncardiovascular events, there were 11 accidental/violent deaths in the cholestyramine group, compared to 4 deaths in the placebo group; 7 of these deaths were suicide/ homicide, and 7 deaths were automobile/motorcycle accidents. Half of these deaths were associated with high alcohol levels. The LRC-CPPT investigators 9 carefully investigated violent deaths to ensure that they were not related to coronary events, but they did not report any association with cholesterol levels, perhaps because of the small number of accidental deaths. The Helsinki Heart Study 10 (a randomized, double-blind controlled trial comparing the effects of gemfibrozil vs placebo) had a slightly higher number of violent deaths in the gemfibrozil group, causing some speculation about a possible relationship between cholesterol level reduction and the risk of violent death. Subsequent to these two clinical trials, several observational studies were summarized by Muldoon et al, 11 showing a relationship between lower serum cholesterol and increased noncardiovascular mortality. In a summary of randomized clinical trial data from dietary and medication lipid-lowering studies, Muldoon et al 11 conclude that there are statistically significant increases in "nonillness" mortality in the cholesterol-lowering groups. 11 Subsequent to these reports, in addition to the POST CABG Trial, there have been eight large randomized, double-blind clinical trials 3,5-8, [33] [34] [35] reporting violent deaths including accidental deaths and suicides. 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) were used in seven trials, 3-8,34 -35 and gemfibrozil was used in one study 33 (Table 8) . When data are summarized from the 10 randomized clinical trials with violent deaths reported, there are nearly equal numbers of violent deaths in the placebo groups (n ϭ 67) and the cholesterol-lowering treatment groups (n ϭ 63). When data from only statin trials are considered, there are slightly greater numbers of violent deaths in the placebo groups (n ϭ 54) than in the statin treatment groups (n ϭ 40). These data from large randomized clinical trials support the concept advanced in the current report that aggressive cholesterol lowering is not associated with adverse psychological changes or an increased risk for violent behavior.
Our data are limited to POST CABG Trial participants for whom data were available throughout the follow-up period; exclusion of patients for whom long-term data are not available, for example because of death, may bias the observations to overall high scores on the HRQL domains. It seems likely that this potential effect would be small, given that the majority of patients not included in these analyses were excluded because data were not collected at baseline, rather than because of loss of patients to follow-up. Further, the low mortality was similar across the treatment groups, and does not change the impression that no differences occurred among treatment groups in HRQL outcomes.
In summary, POST CABG Trial participants did not experience detrimental or beneficial effects on HRQL parameters while receiving LDL cholesterollowering therapy that had demonstrable benefits for treatment of their atherosclerosis. These data support the concept that the recommendation of the National Cholesterol Education Program to lower LDL cholesterol level Ͻ 100 mg/dL in patients with coronary artery disease may be accomplished without apparent adverse effects on HRQL. 36 
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